Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices
January 30, 2021 at 12:40 PM EST
Matridx Biotech of Hangzhou closed a $32 million Series B round to support its pathogen metagenomics devices. GenFleet Therapeutics raised $16 million in a Series B+ round for clinical trials of its two lead oncology candidates in China and the US.
